Milestones and Achievements in the Bio-Technopark

Successes 2017 – 2019

 

2018

  • Kuros announces final result of capital increase – total gross proceeds of CHF 16.1 million raised.
  • ProteoMediX raises CHF 5.2 million in financing round.
  • InSphero receives additional $10 million for organ-on-a-chip disease models. The latest funding round with additional financing, secured from internal and external investors, bringing its total funding to date to $35 million.
  • Neurimmune receives a one-time $50 million payment from its collaboration partner Biogen in exchange for a 5% reduction in the previously negotiated royalty rates on aducanumab.
  • The University Hospital Zurich (USZ), in cooperation with Roche Pharma (Schweiz) AG and Foundation Medicine Inc, Cambridge USA (FMI), offers a tumor test in the field of personalized cancer medicine. A specialized laboratory was set up in the Bio-Technopark to make the tumor test available to all cancer patients in Switzerland.

2017

  • Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously negotiated royalty rates on aducanumab. Moreover, Neurimmune will receive an additional one-time $50 million payment subject to Biogen’s exercise of an option for an additional 5% royalty buy-down.

Successes 2014 – 2016

 

2016

  • Heptares acquires G7 Therapeutics for CHF 12 million.
  • Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company.
  • Topadur Pharma AG wins Swiss Technology Award 2016 in the category Start-up.
  • Aducanumab, the antibody developed jointly by the University of Zurich, Neurimmune und Biogen, leads to a considerable reduction in harmful beta-amyloid plaques in patients with early forms of Alzheimer’s. As part of a clinical phase Ib trial, treatment with the antibody over a one-year period made the beta-amyloid plaques in the patients’ brains disappear almost completely. The results were published in the prestigious journal Nature.
  • Cell Medica, a leader in the development, manufacturing, and marketing of cellular therapeutics to treat cancer and viral infections, acquires Delenex Therapeutics.
  • In Stockholm, NeMoDevices AG receives the Eurostars Innovation Award for the project “Opto-Brain”, which is deemed to be the best of a thousand Eurostar projects.
  • Cytos Biotechnology AG merges with the Zurich-based company, Kuros Biosurgery Holding AG, and is renamed Kuros Biosciences AG.

2015

  • Neurimmune receives major US$60 million development milestone upon initiation of global phase 3 studies with Aducanumab for early Alzheimer’s disease.
  • InSphero AG secures CHF 20 million series C financing.
  • GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid $190 million to purchase the remaining stake in the company, which is valued at $212 million in total.
  • Pfizer acquires Redvax GmbH, a Swiss biopharmaceutical company that is a spin-off from Redbiotec AG.

2014

  • Total offer size of Molecular Partner’s IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option.
  • FierceBiotech names Molecular Partners as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
  • 100 experts vote for InSphero as the best Swiss Start-up.
  • Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson acquires Covagen AG, an ETH spin-off specializing in the development of multi-specific protein therapeutics through the FynomAb® technology platform.
  • Thermo Fisher Scientific expands animal diagnostics business through acquisition of Prionics AG.

Successes 2011 – 2013

 

2013

  • Covagen secures CHF 42 million in a tranched Series B financing with an option to obtain an additional CHF 14 million that would increase the total amount of the financing round to CHF 56 million. This is one of the largest private financing rounds for a preclinical-stage biotech company in Europe.
  • Roche and Molecular Partners enter into alliance to develop new cancer treatment. Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology. Molecular Partners is entitled to receive upfront and initiation payments up to CHF 55 million. Furthermore, Molecular Partners will receive research funding and can earn more than CHF 1 billion if all development and sales milestones are met for all potential products. In addition Molecular Partners will receive tiered royalties on any future product sales into the double-digit percentage range.
  • Roche gains FDA approval with breakthrough therapy designation for its chronic lymphocytic leukemia agent Obinutuzumab which was discovered at Roche Glycart in Schlieren.
  • InSphero ranks no. 5 of the 100 best start-ups in Switzerland.
  • The University of Zurich opens new research facilities in the Bio-Technopark.
  • The University Hospital commissions an innovative integrated PET/MRI scanner for state-of-the-art imaging in the fields of oncology, neurology, and cardiac diagnostics.
  • The first of four planned 11-story buildings is inaugurated.

2012

  • ProteoMediX AG has been awarded the Swiss Technology Award 2012 in the category start-up.
  • Covagen announced that it has entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and its fully owned subsidiary Tanabe Research Laboratories U.S.A., Inc. of San Diego Calif. (TRL). For the global, exclusive rights to bispecific FynomAbs against one target pair, Mitsubishi Tanabe will pay to Covagen EUR 4.0 million upfront. Under the agreement, Mitsubishi Tanabe will fund all research activities and be solely responsible for the development, manufacturing and global commercialization activities. Upon achievement of certain research, development and regulatory milestones, Covagen will be entitled to receive payments of up to EUR 108.25 million for FynomAbs against the first target pair as well as tiered royalties on worldwide net sales of products resulting from the collaboration.
  • Business Acquisition: Scanco Medical AG to acquire b-cube AG Scanco Medical AG and b-cube AG are pleased to announce that the two companies have entered negotiations for Scanco Medical to acquire b-cube in mutual agreement.
  • Allergan, Inc. (NYSE: AGN) and Molecular Partners AG announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases. Molecular Partners will receive combined upfront payments of USD 62.5 million under the two agreements and is eligible to receive additional success-based payments, including up to USD 1.4 billion in aggregate development, regulatory and sales milestones, and tiered royalties up into the low double-digits for future product sales.
  • Cytos to raise up to CHF 37 million from international and strategic investors to advance asthma clinical program.

2011

  • Molecular Partners enters into a strategic research collaboration and option agreement with Janssen Biotech, Inc. in immunology to develop multispecific DARPins®. Molecular Partners will receive significant upfront fees, license payments and research funding as part of an innovative agreement, as well as development and sales milestones of up to USD 200 million for each option. Upon commercialization, Molecular Partners will be entitled to a tiered and up to double-digit royalty on worldwide net sales.
  • Sunstar Suisse SA acquires ETH spin-off Degradable Solutions.
  • BiognoSYS, Covagen, NemoDevices, Neurimmune und Redbiotec belong to the Top 100 Start-ups in Switzerland.
  • Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal disease. Molecular Partners will receive an up-front payment of USD 45 million and is further entitled to receive additional payments of up to an aggregate of USD 375 million upon meeting certain development, regulatory and sales milestones. In addition, Molecular Partners will receive tiered double-digit royalties on any future sales of MP0112.

Successes 2008 – 2010

 

2010

  • Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs. Biogen Idec will make an initial payment of USD 32.5 million and up to USD 395 million in contingent payments.
  • Molecular Partners has been selected as a World Economic Forum Technology Pioneer 2011.
  • The Biotech Center Zurich becomes a member of the Technopark Alliance, and its name is changed to Bio-Technopark Schlieren-Zurich.

2009

  • Molecular Partners secures CHF 46 million in Series B financing.
  • US company Alcon acquires ESBATech AG for USD 150 million in cash and up to USD 439 million based upon achievement of future milestones. The rights to the technology and products for application outside of ophtalmology will be retained by the previous shareholders of ESBATech and spun off into a separate new company, Delenex Therapeutics AG.
  • Merger of biotop Life Science Incubator Schlieren and Biotech Center Zurich, and the setting up of a branch office.

2008

  • Series B financing round amounting to more than CHF 73 million by ESBATech AG.
  • CHF 150 million collaboration between Cytos Biotechnology AG and Pfizer Inc.

Successes 1984 – 2007

 

2007

  • CHF 600 million collaboration between Cytos Biotechnology AG and Novartis AG.
  • USD 380 million collaboration between Neurimmune Therapeutics AG and Biogen Idec Inc.

2005

  • Roche acquires Glycart Biotechnology AG for CHF 235 million.

2004

  • Prionics AG wins the BioTechnica Award and Cytos Biotechnology AG ranks third.

2003

  • Biotech Center Zurich is established, and the Swiss Federal Councilor at the time, Kaspar Villiger, pays a visit.
  • Inauguration of Life-Science-Inkubators biotop.

2002

  • Inauguration of the Biotech Center Zurich by Swiss Federal Councilor at the time, Pascal Couchepin
  • Notation on the stock market of Cytos Biotechnology AG

2000

  • Dr. Jörg Mayer has the first concrete plans for the creation of a life science park in Schlieren.

1998

  • Cytos Biotechnology AG moves into a former ETH laboratory.

1986

  • Laboratories are put into operation on Wagistrasse for the Swiss Federal Institute of Technology (ETH) institutes.

1984

  • The company Schweizerische Wagons- und Aufzügefabrik AG closes down and a large part of the “Wagi” site is taken over by the company Gewerbe- und Handelszentrum Schlieren AG.